To amend the Federal Food, Drug, and Cosmetic Act to establish special rules to provide for continued review of human drug and device submissions during a lapse of appropriations, and for other purposes.
See how your representatives voted on this bill.
DeepSyte matches this bill to the issues you care about and shows whether your reps' votes line up — not party, not press releases. Take the 2-minute values quiz to see your alignment.
Alignment with your views
Sign in and take the values quiz to see how this bill lines up with what you've said.
Summary
Based on the bill's title, this legislation would amend the Federal Food, Drug, and Cosmetic Act to establish procedures allowing the FDA to continue reviewing human drug and device submissions during federal government funding lapses (shutdowns). The bill aims to ensure that pharmaceutical and medical device review processes are not interrupted when appropriations expire.
Values analysis
Sign in and take the values quiz to get a personalized read on how this bill lines up with your positions.
How your representatives voted
Sign in to see how your representatives voted on this bill.